coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)

被引：8

作者：

Paolo A Ascierto

Grant A. McArthur

Brigitte Dréno

James Larkin

Gabriella Liszkay

Michele Maio

Mario Mandala

Lev Demidov

Daniil Stroyakovskiy

Luc Thomas

Luis de la Cruz-Merino

Victoria Atkinson

Caroline Dutriaux

Claus Garbe

Ilsung Chang

Stephen P. Hack

Antoni Ribas

机构：

[1] Istituto Nazionale Tumori Fondazione G. Pascale,

[2] Peter MacCallum Cancer Centre,undefined

[3] Hôtel Dieu Place Alexis Ricordeau,undefined

[4] The Royal Marsden Hospital,undefined

[5] National Institute of Oncology,undefined

[6] Azienda Ospedaliera Universitaria Senese,undefined

[7] Papa Giovanni XXIII Hospital,undefined

[8] N.N. Blokhin Russian Cancer Research Center,undefined

[9] Moscow City Oncology Hospital 62,undefined

[10] Centre Hospitalier Lyon Sud,undefined

[11] Hospital Universitario Virgen Macarena,undefined

[12] Princess Alexandra Hospital,undefined

[13] Hopital Saint André,undefined

[14] University of Tübingen,undefined

[15] Genentech,undefined

[16] Inc,undefined

[17] Jonsson Comprehensive Cancer Center at the University of California,undefined

[18] Los Angeles,undefined

来源：

Journal of Translational Medicine | / 13卷 / Suppl 1期

关键词：

Overall Survival; Metastatic Melanoma; Vemurafenib; Creatine Phosphokinase; BRAF Inhibitor;

D O I：

10.1186/1479-5876-13-S1-O4

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[41] Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study
Fassnacht, Martin
Berruti, Alfredo
Baudin, Eric
Demeure, Michael J.
Gilbert, Jill
Haak, Harm
Kroiss, Matthias
Quinn, David I.
Hesseltine, Elizabeth
Ronchi, Cristina L.
Terzolo, Massimo
Choueiri, Toni K.
Poondru, Srinivasu
Fleege, Tanya
Rorig, Ramona
Chen, Jihong
Stephens, Andrew W.
Worden, Francis
Hammer, Gary D.
LANCET ONCOLOGY, 2015, 16 (04): : 426 - 435
[42] PACIFIC: A Double-Blind, Placebo-Controlled Phase 3 Study of Durvalumab as Consolidation Therapy After Chemoradiation in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer
Antonia, S. J.
Villegas, A.
Daniel, D.
Baz, D. Vincente
Murakami, S.
Hui, R.
Yokoi, T.
Chiappori, A.
Lee, K. H.
de Wit, M.
Cho, B. C.
Bourhaba, M.
Quantin, X.
Tokito, T.
Mekhail, T.
Planchard, D.
Jiang, H.
Huang, Y.
Dennis, P. A.
Ozguroglu, M.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (05): : 1314 - 1315
[43] Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
Kudo, Masatoshi
Cheng, Ann-Lii
Park, Joong-Won
Park, Jae Hyung
Liang, Po-Chin
Hidaka, Hisashi
Izumi, Namiki
Heo, Jeong
Lee, Youn Jae
Sheen, I-Shyan
Chiu, Chang-Fang
Arioka, Hitoshi
Morita, Satoshi
Arai, Yasuaki
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (01): : 37 - 46
[44] RENAVIV: A randomized phase III, double-blind, placebo-controlled study of pazopanib with or without abexinostat in patients with locally advanced or metastatic renal cell carcinoma.
Aggarwal, Rahul Raj
Thomas, Scott
Hauke, Ralph J.
Nordquist, Luke T.
Munster, Pamela N.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[45] International randomized, double-blind, placebo-controlled, phase 3 study of linsitinib (OSI-906, L) in patients (pts) with locally advanced or metastatic adrenocortical carcinoma (ACC).
Quinn, David I.
Baudin, Eric
Demeure, Michael J.
Fassnacht, Martin
Hammer, Gary D.
Poondru, Srinivasu
Fleege, Tanya
Rorig, Ramona
Berruti, Alfredo
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[46] International Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Linsitinib (OSI-906, L) in Patients (pts) with Locally Advanced or Metastatic Adrenocortical Carcinoma (ACC)
Fassnacht, Martin
Baudin, Eric
Demeure, Michael J.
Fleege, Tanya
Poondru, Srinivasu
Quinn, David I.
Rorig, Ramona
Hammer, Gary D.
ENDOCRINE REVIEWS, 2014, 35 (03)
[47] A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF HEDGEHOG PATHWAY INHIBITOR (HPI) GDC-0449 IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC)
Berlin, J.
Bendell, J.
Hart, L. L.
Firdaus, I.
Gore, I.
Hermann, R. C.
Mackey, H.
Yauch, B.
Graham, R. A.
Bray, G. L.
ANNALS OF ONCOLOGY, 2010, 21 : 10 - 10
[48] AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adult Patients with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation
Montesinos Fernandez, Pau
Recher, Christian
Doronin, Vadim
Calado, Rodrigo T.
Jang, Jun Ho
Miyazaki, Yasushi
Wang, Jianxiang
Gianolio, Diego A.
Daigle, Scott R.
Winkler, Thomas
Zhang, Vickie
Paschka, Peter
BLOOD, 2019, 134
[49] MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC)
Van Cutsem, Eric
Lenz, Heinz-Josef
Furuse, Junji
Tabernero, Josep
Heinemann, Volker
Ioka, Tatsuya
Bazin, Igor
Ueno, Makoto
Csoszi, Tibor
Wasan, Harpreet
Melichar, Bohuslav
Karasek, Petr
Macarulla, Teresa Mercade
Guillen, Carmen
Kalinka-Warzocha, Ewa
Horvath, Zsolt
Prenen, Hans
Schlichting, Michael
Ibrahim, Ayman
Bendell, Johanna C.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[50] Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Cortes, Javier
Cescon, David W.
Rugo, Hope S.
Nowecki, Zbigniew
Im, Seock-Ah
Yusof, Mastura Md
Gallardo, Carlos
Lipatov, Oleg
Barrios, Carlos H.
Holgado, Esther
Iwata, Hiroji
Masuda, Norikazu
Torregroza Otero, Marco
Gokmen, Erhan
Loi, Sherene
Guo, Zifang
Zhao, Jing
Aktan, Gursel
Karantza, Vassiliki
Schmid, Peter
LANCET, 2020, 396 (10265): : 1817 - 1828

← 1 2 3 4 5 →